Document:

EX-10.15

 Exhibit 10.15 

 

			
	

	  	 Steven Kemper, CPA, MBA

CFO/Treasurer

 11099 N. Torrey Pines Road, Suite 100 

La Jolla, CA 92037 
 Direct: 858.450.4222 

Fax: 858.200.3877 
 www.dermtech.com  

December 7, 2018 
 Todd Wood 

Dana Point, CA 
 (949) 374–6260 ● tm_wood@me.com

  

	RE:	 OFFER OF EMPLOYMENT 

Dear Todd, 
 DermTech is pleased to offer you employment as
Chief Commercial Officer at an annual salary of $275,000. You will report to John Dobak, CEO. You will be eligible for a $25,000 bonus in 2019 upon the close of financing with a new investor syndicate after which your base salary would be adjusted
to $300,000. In addition, you will be eligible for a 30% bonus of your base salary that would be based upon corporate and individual sales goals that will be determined at a later date by the CEO and Board of Directors. This is a full-time position
and you will be expected to devote 100% of your working time to DermTech. We expect you to be available to work out of our office 3-4 days per week and 2-3 weeks per
month, depending on your travel schedule. We would pay for your hotel expense 6 months should you need to stay or desire to stay overnight. 
 You will be
required to complete our standard Employee Nondisclosure, Confidentiality and Invention Assignment Agreement that will be sent to you shortly. This offer is contingent upon successful completion of a background and reference check. Your employment
is at-will meaning either you or the company can terminate the employment at any time without notice. 

Termination for other than cause, death or disability: 

If the Company (or any parent or subsidiary or successor of the Company) terminates your employment with the Company other than for cause, death or disability
then you will be entitled to receive a lump sum payment of severance equal to three months of your base salary, less applicable withholdings. 

Termination for cause, death or disability: 
 If your
employment with the Company (or any parent or subsidiary or successor of the Company) is terminated voluntarily by you, for cause by the Company or due to your death or disability, then: (i) all vesting will terminate immediately upon
termination with respect to your outstanding equity awards and (ii) all payments of compensation by the Company to you will terminate immediately upon termination (except as to amounts already earned). 

Upon acceptance of this offer of employment, you will be eligible to be included in our medical/dental/vision coverage through Anthem (medical) and MetLife
(dental and vision). These benefits are currently paid 90% by the Company for employees and 50% of the cost for dependent coverage, but is subject to change in the future. Depending on your elections, DermTech will pay all or a portion your
benefits. DermTech also offers a 401(k) plan; the company does not match at this time. Subject to Board approval, we will provide you with a 1.5% equity stake in DermTech through either restricted stock units or stock options that will vest over 4
years. You will also be eligible for 18 days Paid-time-off (PTO) that you will accrue annually and a $100 per month cell phone allowance. In addition, you will be eligible for 5 additional paid time off
compensation days that will not be part of your annual accrual. 

 Your start date is Monday, January 14, 2019. Please sign your acceptance below and we look forward to
working with you! 
  

	
	Sincerely
	
	/s/ John Dobak
	
	John Dobak, CEO

  

			
	Offer Accepted:
		
	Sign:	 	 /s/ Todd Wood

	Print Name:	 	Todd Wood
	Date:	 	December 9, 2018EX-10.16

 Exhibit 10.16 

 

			
	 

	 	 Steven Kemper, CPA, MBA

CFO/Treasurer

 11099 N. Torrey Pines Road, Suite 100 

La Jolla, CA 92037 
 Direct: 858.450.4222 

Fax: 858.200.3877 
 www.dermtech.com 

Burkhard Jansen 
 1319 Caminito Arriata 

La Jolla, CA 92037 
  

	RE:	 OFFER OF EMPLOYMENT 

Dear Burkhard, 
 DermTech is pleased to offer you employment as
VP of Clinical Development at an annual salary of $240,000 per year. You will be able to participate in our bonus plan up to 20% of your salary starting in 2016. Your bonus goals will be set in December 2015 for the 2016 calendar year by the board
of directors and the CEO. You will report to the CEO. You have already been granted stock options in the range of a Vice President position. If subsequent to an acquisition of DermTech by another company you are terminated within one year following
the acquisition, and the acquiring company does not assume the liability for your stock options, 100% of your unvested options will then vest. This is a full-time position and you will be expected to be available via phone or email when not in the
office. You will be required to complete our standard Employee Nondisclosure, Confidentiality and Invention Assignment Agreement that will be sent to you shortly. Your employment is at-will meaning either you
or the company can terminate the employment at any time without notice. You must provide documents proving your right to work in the United States. 
 The
only modification to your at-will status is as follows: If you are terminated without cause, in exchange for releasing the company and its assigns of any and all liability, in a form provided to you by the
company, you will be granted three months of severance at your then current salary. If you are terminated for cause or for death or disability, no severance will be due. 

Upon acceptance of this offer of employment, you will be eligible to be included in our medical/dental/vision coverage through Anthem Blue Cross and Barney
and Barney. These benefits are paid 100% by the Company for employees and one-third of the cost for dependent coverage. DermTech also offers a 401 (k) plan; the company does not match at this time. You will
also be eligible for 3 weeks Paid-time-off (PTO) and cell phone reimbursement. 
 Your start date is October 1,
2015. 
 Please sign your acceptance below and we look forward to working with you again! 

 

	
	Sincerely
	
	 /s/ Steve Kemper

	Steve Kemper, CFO and Treasurer

  

			
	Offer Accepted:
		
	Sign:	 	 /s/ Burkhard Jansen

	Print Name	 	Burkhard Jansen, MD
	Date:	 	Oct 1, 2015EX-10.17

 Exhibit 10.17 

DERMTECH, INC. 

AMENDED AND RESTATED 

VOTING AGREEMENT 

This Amended and Restated Voting Agreement (the “Agreement”) effective as of September 26, 2017 by and among DermTech,
Inc., a Delaware corporation (the “Company”), the holders of shares of Common Stock listed on Exhibit A-1 (individually, a “Common Holder” and collectively, the
“Common Holders”), the Existing Investors (as defined below) listed on Exhibit A-2, and the purchasers of Series C Preferred Stock (the “Purchasers”) listed on
Exhibit A-3. The holders of Series C Preferred Stock are individually referred to as a “Preferred Holder” and collectively as the “Preferred Holders”). The Common
Holders, the Existing Investors and the Preferred Holders are collectively referred to herein as the “Stockholders.” The Company’s Series C Preferred Stock is collectively referred to herein as the “’Preferred
Stock.” 
 RECITALS 

WHEREAS, certain of the parties hold shares of the Company’s Series C Preferred Stock and/or shares of the Company’s Common
Stock issued on conversion of the Company’s former Series A-1, Series A-2, Series A-3 and Series B Preferred Stock (the
“Existing Investors”) and possess certain voting rights. 
 WHEREAS, the Common Holders, the Existing Investors, and
certain of the Preferred Holders (together, the “Prior Holders”) are party to that certain Amended and Restated Voting Agreement dated October 7, 2016 by and among the Company and the Prior Holders, as amended (the
“Prior Agreement”). 
 WHEREAS, the Company and the Purchasers are entering into an Amended and Restated Series C
Preferred Securities Purchase Agreement of even date herewith (the “Purchase Agreement”), and it is a condition to the closing of the sale of the Series C Preferred Stock to the Purchasers that such Purchasers and the Company
execute and deliver this Agreement. 
 WHEREAS, it is a further condition to the closing of the sale of the Series C Preferred Stock
pursuant to the Purchase Agreement that Prior Holders holding sufficient shares to amend the Prior Agreement execute and deliver this Agreement and agree that this Agreement will supersede and replace the Prior Agreement in its entirety. 

WHEREAS, the Company and the Prior Holders desire to amend and restate the Prior Agreement and to enter into this Agreement with the
Purchasers. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained, and other consideration, the
receipt and adequacy of which is hereby acknowledged, the parties hereto agree as follows: 

  
 1 

 AGREEMENT 

 

	 	1.	 Election of Directors. 

1.1    Board Representation. At each annual meeting of the stockholders of the Company, or at any meeting of
the stockholders of the Company at which members of the Board of Directors of the Company (the “Board of Directors”) are to be elected, or whenever members of the Board of Directors are to be elected by written consent, the
Stockholders shall vote or act with respect to their shares so as to elect: 
 (a)    the Company’s Chief
Executive Officer, initially John Dobak, as a director elected by the holders of Preferred Stock and Common Stock, voting together as a single class on an as-converted basis; provided that if for some
reason he or she shall cease to serve as the Company’s Chief Executive Officer, each of the Stockholders shall promptly vote their respective shares (i) to remove the former Chief Executive Officer from the Board of Directors if such
person has not resigned as a member of the Board of Directors and (ii) to elect such person’s replacement as the Company’s Chief Executive Officer as a director; 

(b)     one (1) director to be designated by Jacobs Investment Company LLC as one of the directors elected by the
holders of Preferred Stock and Common Stock, voting together as a single class on an as-converted basis, provided, however, if Jacobs Investment Company LLC no longer holds at least 500,000 shares of
the Company’s capital stock at any time, this right to designate a director shall terminate; and 
 (c)    one
(1) director to be designated by RTW Master Fund, LTD and RTW Innovation Master Fund, LTD (together,“RTW”) as the director elected by RTW (the “RTW Director”); provided, however, that RTW’s
right to designate the RTW Director under this Section 1.1(c) shall be subject to and contingent upon the completion of the Second Tranche Investment (as defined in the Purchase Agreement), and RTW shall have no right to designate the RTW
Director unless and until such time that RTW purchases the Second Tranche Investment Amount (as defined in the Purchase Agreement) from the Company in the Second Tranche Closing; provided further, however, if RTW no longer holds at least 60%
of the Preferred Stock purchased by RTW under the Purchase Agreement at any time after the Second Tranche Closing (as defined in the Purchase Agreement), this right to designate a director shall terminate immediately with no further action required
by the Company or RTW. 
 1.2    Failure to Designate a Board Member. In the absence of any designation
from the persons or groups with the right to designate a director as specified above, the director previously designated by them and then serving shall be reelected if still eligible to serve as provided herein. 

1.3    Removal. Each Stockholder also agrees to vote, or cause to be voted, all shares of the Company’s
capital stock owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that: 

(a)    no director elected pursuant to Section 1.1 above may be removed from office other than for cause unless
(i) such removal is directed or approved by the 

  
 2 

 
affirmative vote of the person or persons, entitled under Section 1.1 to designate that director or (ii) the person(s) originally entitled to designate or approve such director or
occupy such Board seat pursuant to Section 1.1 is no longer so entitled to designate or approve such director or occupy such Board seat; 

(b)    any vacancies created by the resignation, removal or death of a director elected pursuant to Section 1.1
shall be filled pursuant to the provisions of this Section 1; and 
 (c)    upon the written request of the
persons entitled to designate a director as provided in Section 1.1 to remove such director, such director shall be removed. 
 All
Stockholders agree to execute any written consents required to perform the obligations of this Agreement, and the Company agrees at the request of any party entitled to designate directors to call a special meeting of stockholders for the purpose of
electing directors. 
 1.4    No Liability for Election of Recommended Directors. No Stockholder, nor any
Affiliate of any Stockholder, shall have any liability as a result of designating a person for election as a director for any act or omission by such designated person in his or her capacity as a director of the Company, nor shall any Stockholder
have any liability as a result of voting for any such designee in accordance with the provisions of this Agreement. For purposes of this Agreement, “Person” means an individual, firm, corporation, partnership, association, limited
liability company, trust or any other entity. For purposes of this Agreement, “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by or is under common
control with, such Person, including without limitation any general or limited partner, managing member, officer or director of such Person. 

1.5    No “Bad Actor” Designees. Each Person with the right to designate or participate in the
designation of a director as specified above hereby represents and warrants to the Company that, to such Person’s knowledge, none of the “bad actor” disqualifying events described in Rule 506(d)(1)(i)-(viii) promulgated under the
Securities Act of 1933, as amended (the “Securities Act”) (each, a “Disqualification Event”), is applicable to such Person’s initial designee named above except, if applicable, for a Disqualification Event as
to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable. Any director designee to whom any Disqualification Event is applicable, except for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable, is
hereinafter referred to as a “Disqualified Designee.” Each Person with the right to designate or participate in the designation of a director as specified above hereby covenants and agrees (A) not to designate or participate in
the designation of any director designee who, to such Person’s knowledge, is a Disqualified Designee and (B) that in the event such Person becomes aware that any individual previously designated by any such Person is or has become a
Disqualified Designee, such Person shall as promptly as practicable take such actions as are necessary to remove such Disqualified Designee from the Board and designate a replacement designee who is not a Disqualified Designee. 

2.    Vote to Increase Authorized Common Stock. Each Stockholder agrees to vote or cause to be voted
all shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to 

  
 3 

 
increase the number of authorized shares of Common Stock from time to time to ensure that there will be sufficient shares of Common Stock available for conversion of all of the shares of
Preferred Stock outstanding at any given time. 
  

	 	3.	 Drag-Along Right. 

3.1    Definitions. A “Sale of the Company” shall mean either: (a) a transaction or
series of related transactions in which a Person, or a group of related Persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a “Stock
Sale”); or (b) a transaction that qualifies as a “Deemed Liquidation Event” as defined in the Restated Certificate. 

3.2    Actions to be Taken. In the event that (i) the holders of at least 50% of the shares of Common
Stock then issued or issuable upon conversion of the shares of Series C Preferred Stock (the “Selling Investors”); (ii) the Board of Directors; (iii) the holders of a majority of the then outstanding shares of Common Stock
(other than those issued or issuable upon conversion of the shares of Series C Preferred Stock); and (iv) RTW (collectively, the “Electing Holders”) approve a Sale of the Company in writing, specifying that this Section 3
shall apply to such transaction, then each Stockholder and the Company hereby agree: 
 (a)    if such transaction
requires stockholder approval, with respect to all shares that such Stockholder owns or over which such Stockholder otherwise exercises voting power, to vote (in person, by proxy or by action by written consent, as applicable) all shares in favor
of, and adopt, such Sale of the Company (together with any related amendment to the Restated Certificate required in order to implement such Sale of the Company) and to vote in opposition to any and all other proposals that could reasonably be
expected to delay or impair the ability of the Company to consummate such Sale of the Company; 
 (b)    if such
transaction is a Stock Sale, to sell the same proportion of shares of capital stock of the Company beneficially held by such Stockholder as is being sold by the Selling Investors to the Person to whom the Selling Investors propose to sell their
Shares, and, except as permitted in Subsection 3.3 below, on the same terms and conditions as the Selling Investors; 

(c)    to execute and deliver all related documentation and take such other action in support of the Sale of the Company
as shall reasonably be requested by the Company or the Selling Investors in order to carry out the terms and provision of this Section 3, including, without limitation, executing and delivering instruments of conveyance and transfer, and any
purchase agreement, merger agreement, indemnity agreement, escrow agreement, consent, waiver, governmental filing, share certificates duly endorsed for transfer (free and clear of impermissible liens, claims and encumbrances), and any similar or
related documents; 
 (d)    not to deposit, and to cause their Affiliates not to deposit, except as provided in this
Agreement, any shares of the Company owned by such party or Affiliate in a voting trust or subject any shares to any arrangement or agreement with respect to the voting of such shares, unless specifically requested to do so by the acquiror in
connection with the Sale of the Company; 

  
 4 

 (e)    to refrain from exercising any dissenters’ rights or rights
of appraisal under applicable law at any time with respect to such Sale of the Company; 
 (f)    if the consideration
to be paid in exchange for the shares pursuant to this Section 3 includes any securities and due receipt thereof by any Stockholder would require under applicable law (x) the registration or qualification of such securities or of any
person as a broker or dealer or agent with respect to such securities; or (y) the provision to any Stockholder of any information other than such information as a prudent issuer would generally furnish in an offering made solely to
“accredited investors” as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to any such Stockholder in lieu thereof, against surrender of the shares which would have otherwise been sold by such
Stockholder, an amount in cash equal to the fair value (as determined in good faith by the Company) of the securities which such Stockholder would otherwise receive as of the date of the issuance of such securities in exchange for the shares; and

 (g)    in the event that the Selling Investors, in connection with such Sale of the Company, appoint a stockholder
representative (the “Stockholder Representative”) with respect to matters affecting the Stockholders under the applicable definitive transaction agreements following consummation of such Sale of the Company, (x) to consent to
(i) the appointment of such Stockholder Representative, (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the payment of such
Stockholder’s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative’s services and
duties in connection with such Sale of the Company and its related service as the representative of the Stockholders, and (y) not to assert any claim or commence any suit against the Stockholder Representative or any other Stockholder with
respect to any action or inaction taken or failed to be taken by the Stockholder Representative in connection with its service as the Stockholder Representative, absent fraud or willful misconduct. 

3.3    Exceptions. Notwithstanding the foregoing, a Stockholder will not be required to comply with
Subsection 3.2 above in connection with any proposed Sale of the Company (the “Proposed Sale”), unless: 

(a)    any representations and warranties to be made by such Stockholder in connection with the Proposed Sale are limited
to representations and warranties related to authority, ownership and the ability to convey title to such shares, including, but not limited to, representations and warranties that (i) the Stockholder holds all right, title and interest in and
to the shares such Stockholder purports to hold, free and clear of all liens and encumbrances, (ii) the obligations of the Stockholder in connection with the transaction have been duly authorized, if applicable, (iii) the documents to be
entered into by the Stockholder have been duly executed by the Stockholder and delivered to the acquirer and are enforceable against the Stockholder in accordance with their respective terms; and (iv) neither the execution and delivery of
documents to be entered into in connection with the transaction, nor the performance of the Stockholder’s obligations thereunder, will cause a breach or violation of the terms of any agreement, law or judgment, order or decree of any court or
governmental agency; 

  
 5 

 (b)    the Stockholder shall not be liable for the inaccuracy of any
representation or warranty made by any other Person in connection with the Proposed Sale, other than the Company (except to the extent that funds may be paid out of an escrow established to cover breach of representations, warranties and covenants
of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all stockholders); 

(c)    the liability for indemnification, if any, of such Stockholder in the Proposed Sale and for the inaccuracy of any
representations and warranties made by the Company or its Stockholders in connection with such Proposed Sale, is several and not joint with any other Person (except to the extent that funds may be paid out of an escrow established to cover breach of
representations, warranties and covenants of the Company as well as breach by any stockholder of any of identical representations, warranties and covenants provided by all stockholders), and subject to the provisions of the Restated Certificate
related to the allocation of the escrow, is pro rata in proportion to, and does not exceed, the amount of consideration paid to such Stockholder in connection with such Proposed Sale; 

(d)    liability shall be limited to such Stockholder’s applicable share (determined based on the respective
proceeds payable to each Stockholder in connection with such Proposed Sale in accordance with the provisions of the Restated Certificate) of a negotiated aggregate indemnification amount that applies equally to all Stockholders but that in no event
exceeds the amount of consideration otherwise payable to such Stockholder in connection with such Proposed Sale, except with respect to claims related to fraud by such Stockholder, the liability for which need not be limited as to such Stockholder;

 (e)    upon the consummation of the Proposed Sale (i) each holder of each class or series of the Company’s
stock will receive the same form of consideration for their shares of such class or series as is received by other holders in respect of their shares of such same class or series of stock, (ii) each holder of a series of Preferred Stock will
receive the same amount of consideration per share of such series of Preferred Stock as is received by other holders in respect of their shares of such same series, (iii) each holder of Common Stock will receive the same amount of consideration
per share of Common Stock as is received by other holders in respect of their shares of Common Stock, and (iv) unless the holders of at least a majority of the Preferred Stock elect to receive a lesser amount by written notice given to the
Company at least 30 days prior to the effective date of any such Proposed Sale, the aggregate consideration receivable by all holders of the Preferred Stock and Common Stock shall be allocated among the holders of Preferred Stock and Common Stock on
the basis of the relative liquidation preferences to which the holders of each respective series of Preferred Stock and the holders of Common Stock are entitled in a Deemed Liquidation Event (assuming for this purpose that the Proposed Sale is a
Deemed Liquidation Event) in accordance with the Company’s Certificate of Incorporation in effect immediately prior to the Proposed Sale; provided, however, that, notwithstanding the foregoing, if the consideration to be paid in exchange for
any Common Stock or Preferred Stock of the Company, as applicable, pursuant to this Subsection 3.3(e) includes any securities and due receipt thereof by the applicable stockholder would require under applicable law (x) the registration or
qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (y) the provision to the applicable stockholder of any information other than such information as a prudent issuer would
generally 

  
 6 

 
furnish in an offering made solely to “accredited investors” as defined in Regulation D promulgated under the Securities Act, the Company may cause to be paid to the stockholder in lieu
thereof, against surrender of any Common Stock or Preferred Stock of the Company, as applicable, which would have otherwise been sold by such stockholder, an amount in cash equal to the fair value (as determined in good faith by the Company) of the
securities which such stockholder would otherwise receive as of the date of the issuance of such securities in exchange for any Common Stock or Preferred Stock of the Company, as applicable; and 

(f)    subject to clause (e) above, requiring the same form of consideration to be available to the holders of any
single class or series of capital stock, if any holders of any capital stock of the Company are given an option as to the form and amount of consideration to be received as a result of the Proposed Sale, all holders of such capital stock will be
given the same option; provided, however, that nothing in this Subsection 3.3(f) shall entitle any holder to receive any form of consideration that such holder would be ineligible to receive as a result of such holder’s failure to satisfy any
condition, requirement or limitation that is generally applicable to the Company’s stockholders. 

4.    Additional Representations and Covenants. 

4.1    No Revocation. The voting agreements contained herein are coupled with an interest and may not be
revoked during the term of this Agreement. The Company agrees to use commercially reasonable within the requirements of applicable law to ensure that the rights granted under this Agreement are effective and that the parties enjoy the benefits of
this Agreement. Such actions include, without limitation, the use of the Company’s best efforts to cause the nomination and election of the directors as provided in this Agreement. 

4.2    Covenants of the Company. The Company agrees to use commercially reasonable efforts, within the
requirements of applicable law, to ensure that the rights granted under this Agreement are effective and that the parties enjoy the benefits of this Agreement. Such actions include, without limitation, the use of the Company’s commercially
reasonable to cause the nomination and election of the directors as provided in this Agreement. 

4.3    Specific Enforcement. Each party acknowledges and agrees that each party hereto will be irreparably
damaged in the event any of the provisions of this Agreement are not performed by the parties in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that each of the Company and the Stockholders shall be
entitled to an injunction to prevent breaches of this Agreement, and to specific enforcement of this Agreement and its terms and provisions in any action instituted in any court of the United States or any state having subject matter jurisdiction.

 4.4    Remedies Cumulative. All remedies, either under this Agreement or by law or otherwise afforded
to any party, shall be cumulative and not alternative. 
 4.5    Transfers. Each transferee or assignee of
any shares held by a party to this Agreement and subject to the terms hereof shall continue to be subject to the terms hereof, and, as a condition precedent to the Company’s recognizing such transfer, each transferee or assignee shall agree in
writing to be subject to each of the terms of this Agreement by executing 

  
 7 

 
and delivering an adoption agreement in a form acceptable to the Company. Upon the execution and delivery of an adoption agreement by any transferee, such transferee shall be deemed to be a party
hereto as if such transferee were the transferor and such transferee’s signature appeared on the signature pages of this Agreement and shall be deemed to be an Investor and Stockholder, or Key Holder and Stockholder, as applicable. The Company
shall not permit the transfer of the shares subject to this Agreement on its books or issue a new certificate representing any such shares unless and until such transferee shall have complied with the terms of this Subsection 3.5. Each
certificate instrument, or book entry representing the shares subject to this Agreement if issued on or after the date of this Agreement shall be notated by the Company with the legend set forth in Subsection 3.6. 

4.6    Legends. Each certificate representing shares of the Company’s capital stock held by the
Stockholders or any assignee of the Stockholders shall bear the following legend: 
 “THE SHARES EVIDENCED HEREBY ARE SUBJECT TO AN
AMENDED AND RESTATED VOTING AGREEMENT BY AND AMONG THE COMPANY AND CERTAIN STOCKHOLDERS OF THE COMPANY (A COPY OF WHICH MAY BE OBTAINED FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE
DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID VOTING AGREEMENT.” 

5.    Termination. 

5.1    Termination Events. This Agreement shall terminate upon the earliest of: 

(a)    The consummation of a firm commitment underwritten public offering by the Company of shares of its Common Stock in
connection with which all of the outstanding shares of Preferred Stock are converted into shares of Common Stock, pursuant to the Company’s Certificate then in effect; or 

(b)    The consummation of Liquidation Transaction as such term is defined in the Company’s Certificate 

5.2    Removal of Legend. At any time after the termination of this Agreement in accordance with
Section 3.1, any holder of a stock certificate legended pursuant to Section 2.3 may surrender such certificate to the Company for removal of the legend, and the Company will duly reissue a new certificate without the legend. 

6.    Miscellaneous. 

6.1    Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto
pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing between the parties hereto are expressly canceled. 

  
 8 

 6.2    Successors and Assigns. The terms and conditions of
this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

6.3    Amendments and Waivers. Any term hereof may be amended, terminated or waived only with the written
consent of the (i) Company and (ii) the Common Holders, Existing Investors, and Preferred Holders that hold at least 70% of the then outstanding capital stock of the Company (voting together as a single class on an as-converted basis). Notwithstanding the foregoing, (a) this Agreement may be amended with only the consent of the Company for the sole purpose of including additional Purchasers as “Preferred
Holders.” Section 1.1(c) may not be amended without the consent of either RTW Master Fund, LTD or RTD Innovation Master Fund, LTD, and (b) RTW’s right to approve a sale of the Company pursuant to Section 3.2(vi) for purposes
of Section 3.2 may not be amended or waiver without the written consent of RTW. Any amendment or waiver effected in accordance with this Section 5.3 shall be binding upon the Company, any Preferred Holders and any Common Holder, and each
of their respective successors and permitted assigns. The Company shall give prompt written notice of any amendment, termination or waiver hereunder to any party that did not vote for or consent in writing thereto. 

6.4    Notices. All notices and other communications given or made pursuant to this Agreement shall be in
writing and shall be deemed effectively given upon the earlier of actual receipt or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient,
and if not sent during normal business hours, then on the recipient’s next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day
after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address on the signature
page hereof (or if no address has been provided the last known address of such parties as reflected in the Company’s record), as the case may be, or to such email address, facsimile number or address as subsequently modified by written notice
given in accordance with this Section 6.4. If notice is given to the Company, it shall be sent to 11099 No. Torrey Pines Rd., Suite 100, La Jolla, CA 92037, Attention: Chief Executive Officer; and a copy (which shall not constitute notice)
shall also be sent to Wilson Sonsini Goodrich & Rosati, 12235 El Camino Real, Suite 200, San Diego, CA 92130, Attention: Martin Waters; and if notice is given to the Investors, a copy shall also be given to John Crandon, Esq., 36 Grattan
Street, San Francisco, CA 94117. 
 6.5    Severability. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Agreement, (b) the balance of the Agreement shall be interpreted as if such provision were so excluded and (c) the balance of the Agreement shall be enforceable in accordance with its terms. 

  
 9 

 6.6    Governing Law; Venue. This Agreement and all acts
and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law. The
parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other
proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for
the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject
matter hereof may not be enforced in or by such court. 
 6.7    Counterparts. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 

6.8    Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only
and are not to be considered in construing or interpreting this Agreement. 
 6.9    No Liability for Election
of Recommended Directors. Neither the Company, the Common Holders, the Existing Investors, the Preferred Holders, nor any officer, director, stockholder, partner, employee or agent of any such party, makes any representation or warranty as to
the fitness or competence of the nominee of any party hereunder to serve on the Company’s Board of Directors by virtue of such party’s execution of this Agreement or by the act of such party in voting for such nominee pursuant to this
Agreement. 
 6.10    Termination of Prior Agreement. The Prior Agreement is hereby terminated and shall
have no further force or effect. 
 6.11    Stock Splits, Stock Dividends, etc. In the event of any
issuance of Shares of the Company’s voting securities hereafter to any of the Stockholders (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such Shares shall
become subject to this Agreement and shall be notated with the legend set forth in Subsection 4.6 above. 

6.12    Manner of Voting. The voting of shares pursuant to this Agreement may be effected in person, by
proxy, by written consent or in any other manner permitted by applicable law. For the avoidance of doubt, voting of the shares pursuant to the Agreement need not make explicit reference to the terms of this Agreement. 

6.13    Further Assurances. At any time or from time to time after the date hereof, the parties agree to
cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as 

  
 10 

 
the other party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder.

 6.14    Costs of Enforcement. If any party to this Agreement seeks to enforce its rights under this
Agreement by legal proceedings, the non-prevailing party shall pay all costs and expenses incurred by the prevailing party, including, without limitation, all reasonable attorneys’ fees. 

6.15    Aggregation of Stock. All shares held or acquired by a Stockholder and/or its Affiliates shall be
aggregated together for the purpose of determining the availability of any rights under this Agreement, and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. For the purposes of this
Agreement, the consent or approval of RTW shall be deemed to occur upon the consent or approval of either (i) both RTW Master Fund, LTD and RTW Innovation Master Fund, LTD, (ii) the RTW fund or entity that holds a majority of the Series C
Preferred shares held by all RTW funds or entity. 

  
 11 

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	COMPANY:
	
	DERMTECH INC.
		
	By:	 	/s/ John Dobak
	Name: John Dobak
	Title: President and CEO

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	RTW Master Fund, LTD
		
	By:	 	 /s/ Roderick Wong

	Name: Roderick Wong
	Title: Director
	
	RTW Innovation Master Fund, LTD
		
	By:	 	 /s/ Roderick Wong

	Name: Roderick Wong
	Title: Director

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Roberta Feuerstein Trust DTD 7-9-83
		
	By:	 	 /s/ Roberta Feuerstein

	Name: Roberta Feuerstein Trust DTD 7-9-83
	Title: Trustee

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	/s/ Elliot Feuerstein
	Elliot Feuerstein
	
	Brett Feuerstein Children’s Trust
		
	By:	 	 /s/ Elliot Feuerstein

	Name: Elliot Feuerstein
	Title: Trustee
	
	Michael Feuerstein Children’s Trust
		
	By:	 	 /s/ Elliot Feuerstein

	Name: Elliot Feuerstein
	Title: Trustee
	
	Elliot Feuerstein Trust DTD 5-14-83
		
	By:	 	 /s/ Elliot Feuerstein

	Name: Elliot Feuerstein
	Title: Trustee
	
	Mesa Shopping Center East LLC
		
	By:	 	 /s/ Elliot Feuerstein

	Name: Elliot Feuerstein
	Title: Manager
	
	Mesa Shopping Center East LLC
		
	By:	 	 /s/ Elliot Feuerstein

	Name: Elliot Feuerstein
	Title: Manager
	
	Mira Mesa Shopping Center West LLC
		
	By:	 	 /s/ Elliot Feuerstein

	Name: Elliot Feuerstein
	Title: Manager
	
	Mira Mesa Shopping Center LLC
		
	By:	 	 /s/ Elliot Feuerstein

	Name: Elliot Feuerstein
	Title: Manager

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Darakev LP
		
	By:	 	 /s/ Kevin Wechter

	Name: Kevin Wechter
	Title: CEO of Darakev Management LLC its GP

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Paulson DermTech Investments II LLC
		
	By:	 	 /s/ Starla Goff

	Name: Starla Goff
	Title: Officer of the Managing Member

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Paulson DermTech Investments III LLC
		
	By:	 	 /s/ Starla Goff

	Name: Starla Goff
	Title: Officer of the Managing Member

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Paulson DermTech Investments LLC
		
	By:	 	 /s/ Starla Goff

	Name: Starla Goff
	Title: Officer of the Managing Member

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Irwin and Joan Jacobs Family Trust 6-2-80
		
	By:	 	 /s/ Irwin M. Jacobs

	Name: Irwin M. Jacobs
	Title: Trustee

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Louis B. Cushman
	Louis B. Cushman

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Keith Gelles
	Keith Gelles

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Patrick E. Pellecchia
	Patrick E. Pellecchia

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Pacific Equity Ventures, L.P., a California limited partnership
		
	By:	 	 /s/ Andrew M. Kaplan

	Name: Andrew M. Kaplan
	Title: CEO of GP

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Gene Salkind, M.D.
	Gene Salkind, M.D.

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	/s/ Gary E. Jacobs
	Gary Jacobs
	
	Jacobs Investment Company LLC
		
	By:	 	 /s/ Gary E. Jacobs

	Name: Gary E. Jacobs
	Title: Managing Member
	
	Gary E and Jerri-Anne Jacobs Trustees
		
	By:	 	 /s/ Gary E. Jacobs

	Name: Gary E. Jacobs
	Title: Trustee

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Gregory A. Erickson
	Gregory A. Erickson

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	Touchstone Investments Defined Benefit Plan Pension Trust
		
	By:	 	 /s/ Gregory A. Erickson

	Name: Gregory A. Erickson
	Title: Trustee

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ John Dobak
	John Dobak

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Steven M. Wetzner
	Steven M. Wetzner

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Jacob M. Gamble
	Jacob M. Gamble

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Scott R. Pancoast
	Scott R. Pancoast

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Jill M. Olson
	Jill M. Olson

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Ian Katz
	Ian Katz

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Jeremy and Junko Teraoka
	Jeremy and Junko Teraoka

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Cheryl S. Peters
	Cheryl S. Peters

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

			
	PURCHASER:
	
	KT4 Partners LLC
		
	By:	 	 /s/ Marc L. Abramowitz

	Name: Marc L. Abramowitz
	Title: Managing Member

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Zuxu Yao
	Zuxu Yao

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Darryl A. Garrison
	Darryl A. Garrison

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ James A. Rock
	James A. Rock

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Sarah Dion
	Sarah Dion

 The parties hereto have executed this Amended and Restated Voting Agreement as of the date set forth below.

  

	
	PURCHASER:
	
	/s/ Herm Rosenman
	Herm Rosenman

 EXHIBIT A-1 

INVESTORS 
 COMMON HOLDERS: 

 

			
	Name	 	
	The Jacobs Investment Company LLC	 	
	Gene Salkind, M.D.	 	
	Peter Brundage	 	
	Elliot Feuerstein, Trustee for Elliot Feuerstein Trust UTD 5-14-82	 	
	Elliot Feuerstein, Trustee FBO Michael Feuerstein, Feuerstein Children’s Trust UTD 3-15-89	 	
	Elliot Feuerstein, Trustee FBO Brett Feuerstein, Feuerstein Children’s Trust UTD 3-15-89	 	

 EXHIBIT A-2 

INVESTORS 
 EXISTING INVESTORS:

  

			
	Name	 	
	The Jacobs Investment Company LLC	 	
	Gary Jacobs	 	
	Peter Brundage	 	
	Gene Salkind, M.D.	 	
	KT4 Partners LLC	 	
	STOTSKY, Michael S. M.D. Trustee FBO Michael S. Stotsky MPP	 	
	Dennis Logue	 	
	MERG Holdings Pty Ltd.	 	
	Frederick McCarthy	 	
	Elliott Feuerstein	 	
	Elliot Feuerstein, Trustee FBO Michael Feuerstein, Feuerstein Children’s Trust UTD 3-15-89	 	
	Elliot Feuerstein, Trustee FBO Brett Feuerstein, Feuerstein Children’s Trust UTD 3-15-89	 	
	Michael H. Good, M.D.	 	
	James Goode	 	
	Elias Alemesalassie	 	
	Michael McGilveny	 	
	Daniel Einhorn and Emily Feldman Einhorn Trust of 1994	 	
	Patrick E. Pellecchia	 	
	Gregory A. Erickson	 	
	Touchstone Investments Defined Benefit Plan Pension Trust: Gregory A. Erickson, Trustee	 	
	Elliot Feuerstein, Trustee for Elliot Feuerstein Trust UTD 5-14-82	 	
	Darakev LP, a Texas limited partnership	 	
	John Dobak	 	
	Pacific Equity Ventures, L.P., a California limited partnership	 	
	Chitayat Family Gift Trust dated 12/19/2003	 	
	DLA Piper	 	
	WS Investment Company, LLC (2013A)	 	
	Adams Family Trust, UAD 6-34-94	 	

			
	Dana Donovan	 	
	Harmon Spolan	 	
	Jack L. Stahl	 	
	Jill M. Olson	 	
	Likipi Holding SA	 	
	Michael Sanders Stotsky Trust	 	
	Steven M. Wetzner	 	
	Leon Wagner	 	
	Ian Katz	 	
	James Schwering	 	
	Paulson DermTech Investments, LLC	 	
	Keith Gelles	 	
	Bradley Karp	 	
	Jacob M. Gamble	 	
	Kingdom Partners LLC	 	
	Bradley C. & Belinda Karp	 	
	UBS Financial Services Inc. FBO David W. Carey Traditional IRA	 	
	Louis B. Cushman	 	

 EXHIBIT A-3 

INVESTORS 
 PREFERRED HOLDERS: 

 

			
	Name	 	
	Irwin and Joan Jacobs Family Trust 6-2-80	 	
	Gregory A. Erickson	 	
	Pacific Equity Ventures LP	 	
	William C. Skelsey & Maral K. Skelsey JTROS	 	
	Paulson DermTech Investment III, LLC	 	
	Mira Mesa Shopping Center LLC	 	
	Mira Mesa Shopping Center, -West, LLC	 	
	Mesa Shopping Center, - East, LLC	 	
	Elliot Feuerstein Trust DTD 5-14-83	 	
	Roberta Feuerstein Trust DTD 7-9-83	 	
	Darakev, L.P.	 	
	Jeremy and Junko Teraoka	 	
	RTW Master Fund, LTD	 	
	RTW Innovation Master Fund, LTD	 	
	Dana Donovan	 	
	Alcath Dermatology Corp.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]